Table 2.
1.0 mg/kg q2w (Group 1, n = 4) | 3.0 mg/kg q2w (Group 2, n = 4) | 10 mg/kg q2w (Group 3, n = 4) | 15 mg/kg q3w (Group 4, n = 6) | 20 mg/kg q4w (Group 5, n = 4) | Total (N = 22) | |
---|---|---|---|---|---|---|
Any trAE, n (%) | 3 (75) | 3 (75) | 3 (75) | 5 (83) | 2 (50) | 16 (73) |
Rash | 1 (25) | 0 | 1 (25) | 1 (17) | 1 (25) | 4 (18) |
Pruritus | 0 | 2 (50) | 0 | 1 (17) | 0 | 3 (14) |
Constipation | 0 | 2 (50) | 0 | 1 (17) | 0 | 3 (14) |
Nausea | 0 | 1 (25) | 0 | 0 | 2 (50) | 3 (14) |
Stomatitis | 0 | 1 (25) | 0 | 1 (17) | 1 (25) | 3 (14) |
Pyrexia | 1 (25) | 0 | 1 (25) | 0 | 1 (25) | 3 (14) |
q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks; trAE, treatment‐related adverse event.
Safety analysis set.